Cargando…

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium–severe (n = 17) and severe COVID-19 (n = 11). The serum/plasma samples were studied for the presence of IgG, IgM and...

Descripción completa

Detalles Bibliográficos
Autores principales: Desheva, Yulia, Lerner, Anna, Shvedova, Tamara, Kopteva, Olga, Kudar, Polina, Koroleva, Irina, Leontieva, Galina, Suvorov, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045262/
https://www.ncbi.nlm.nih.gov/pubmed/36975366
http://dx.doi.org/10.3390/antib12010019
_version_ 1784913558956408832
author Desheva, Yulia
Lerner, Anna
Shvedova, Tamara
Kopteva, Olga
Kudar, Polina
Koroleva, Irina
Leontieva, Galina
Suvorov, Alexander
author_facet Desheva, Yulia
Lerner, Anna
Shvedova, Tamara
Kopteva, Olga
Kudar, Polina
Koroleva, Irina
Leontieva, Galina
Suvorov, Alexander
author_sort Desheva, Yulia
collection PubMed
description In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium–severe (n = 17) and severe COVID-19 (n = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r(s) = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r(s) = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.
format Online
Article
Text
id pubmed-10045262
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100452622023-03-29 Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity Desheva, Yulia Lerner, Anna Shvedova, Tamara Kopteva, Olga Kudar, Polina Koroleva, Irina Leontieva, Galina Suvorov, Alexander Antibodies (Basel) Article In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium–severe (n = 17) and severe COVID-19 (n = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r(s) = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r(s) = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients. MDPI 2023-02-27 /pmc/articles/PMC10045262/ /pubmed/36975366 http://dx.doi.org/10.3390/antib12010019 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Desheva, Yulia
Lerner, Anna
Shvedova, Tamara
Kopteva, Olga
Kudar, Polina
Koroleva, Irina
Leontieva, Galina
Suvorov, Alexander
Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title_full Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title_fullStr Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title_full_unstemmed Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title_short Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
title_sort pilot study results on antibodies to the s- and n-proteins of sars-cov-2 in paired sera from covid-19 patients with varying severity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045262/
https://www.ncbi.nlm.nih.gov/pubmed/36975366
http://dx.doi.org/10.3390/antib12010019
work_keys_str_mv AT deshevayulia pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT lerneranna pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT shvedovatamara pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT koptevaolga pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT kudarpolina pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT korolevairina pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT leontievagalina pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity
AT suvorovalexander pilotstudyresultsonantibodiestothesandnproteinsofsarscov2inpairedserafromcovid19patientswithvaryingseverity